The Companion Diagnostics Development Services Market

In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise

 


Roots Analysis is pleased to announce the publication of its recent study, titled, “Companion Diagnostics Development Services Market, 2020-2030”

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of more than 180 companies offering companion diagnostics services.

§  Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered).

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  A list of stakeholders generated based on a detailed analysis of a set of relevant parameters, which are anticipated to partner with companion diagnostics services providers in the foreseen future.

§  A detailed competitiveness analysis of companion diagnostics services providers, featuring insightful pictorial summaries and representations.

§  A comparative analysis of the needs of different stakeholders involved in this domain.

§  A discussion on various steps of the development operations of a companion diagnostic and the cost requirements across each of the stages.

§  An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of Services

§  Feasibility Studies

§  Assay Development

§  Analytical Validation

§  Clinical Validation

§  Manufacturing

§  Type of Analytical Technique

§  in situ hybridization / Immunohistochemistry

§  Next Generation Sequencing

§  Polymerase Chain Reaction

§  Others

§  Key Geographical Region 

§  North America

§  Europe

§  Asia-Pacific and the Rest of the World 

 

 

Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Anton Iliuk (President, Chief Technology Officer Tymora Analytical Operations)

§  Paul Kortschak (Senior Vice President, Novodiax)

§  Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)

§  Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

 

 

Key companies covered in the https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

§  Almac Diagnostic Services

§  Asuragen

§  BARD1 Life Sciences

§  BioMarCare Technologies

§  Covance

§  Gencurix

§  Geneuity

§  Leica Biosystems

§  Macrogen

§  MD Biosciences

§  R-Biopharm

§  ResearchDx

§  Tepnel Pharma Services

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

Other Recent Offerings

1.     Neoantigen Targeted Therapies Market, 2019-2030

2.     Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030

3.     Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

Comments

Post a Comment

Popular posts from this blog

The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis

Image
  The recent approval of first RNAi therapeutic, ONPATTRO TM , has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research   London   Roots Analysis has announced the addition of “ RNAi Therapeutics Market (2 nd Edition), 2019-2030 ” report to its list of offerings.   Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.   To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_doc...
Read more

The antibody contract manufacturing market

Image
With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone   Roots Analysis has announced the addition of the “ Antibody Contract Manufacturing Market, 2020-2030 ” report to its list of offerings.   Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and ma...
Read more